Search

Search Results
Results 4821 - 4830 of 4839 for multiple sclerosis
  • Natrilix
    Drug - 26 Jul 2022
    Consumer Medicine Information (CMI) about Natrilix (indapamide) intended for persons living in Australia.
  • Odaplix SR
    Drug - 26 Jul 2022
    Consumer Medicine Information (CMI) about Odaplix SR (Sustained Release tablets containing indapamide) intended for persons living in Australia.
  • Prexum Combi
    Drug - 20 Jul 2022
    Consumer Medicine Information (CMI) about Prexum Combi (perindopril and indapamide) intended for persons living in Australia.
  • Coversyl Plus
    Drug - 20 Jul 2022
    Consumer Medicine Information (CMI) about Coversyl Plus (perindopril and indapamide) intended for persons living in Australia.
  • Prexum
    Drug - 15 Jul 2022
    Consumer Medicine Information (CMI) about Prexum (perindopril) intended for persons living in Australia.
  • An Analytical and Legal Spotlight on Cannabis
    White Paper - 9 Feb 2021
    This article will look at cannabis in relation to an analytical and leag standpoint.
  • How Neurodegenerative Diseases are Affected by Gamma Synuclein Aggregation
    White Paper - 28 Jan 2020
    This article discusses gamma Synuclein aggregation in neurodegenerative diseases.
  • Metabotropic Glutamate Receptor Research Highlights
    White Paper - 6 Jun 2019
    Metabotropic glutamate receptors are exciting therapeutic targets due to their involvement in cardiovascular and neurological diseases, and their widespread expression.
  • Vitamin D Deficiency
    Health - 27 Feb 2019
    Rickets has been around for centuries, but its roots as a symptom of vitamin D deficiency began only in the 17th century, when Francis Glisson published his findings on the disease and proposed that...
  • Elan second quarter total revenue increases 6% to $288.0 million
    News - 25 Jul 2012
    Elan Corporation, plc today reported its second quarter and first half 2012 financial results.

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback